<DOC>
	<DOCNO>NCT01765465</DOCNO>
	<brief_summary>Postcholecystectomy syndrome ( PCS ) include heterogeneous group disease , usually manifest presence abdominal symptom follow gallbladder removal . The pathogenesis PCS identify ; therefore consensus medical treatment PCS . The Action Rowachol inhibit hepatic 3-hydroxy-3-methylglutaric acid ( HMG ) -coenzyme A ( CoA ) reductase , inhibits cholesterol nucleation bile patient cholesterol gallstone , promote biliary lipid secretion . The purpose study determine whether Rowachol useful prevention PCS symptom change laparoscopic cholecystectomy</brief_summary>
	<brief_title>Effect Rowachol Prevention Postcholecystectomy Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Postcholecystectomy Syndrome</mesh_term>
	<criteria>Patients pathologic disease schedule laparoscopic cholecystectomy Current immunosuppressive therapy Chemotherapy within 4 week operation Radiotherapy complete long 4 week operation Inability follow instruction give investigator Severe psychiatric neurologic disease Drug and/or alcoholabuse accord local standard Participation another interventiontrial interference primary secondary endpoint study Lack compliance Lack inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>postcholecystectomy syndrome</keyword>
	<keyword>laparoscopic cholecystectomy</keyword>
	<keyword>Rowachol</keyword>
</DOC>